R emission induction therapy for acute leukemia (AL) requires intensive, cytotoxic treatments, prolonged hospitalizations, and aggressive supportive care including transfusion of blood products (red blood cells [RBCs] , platelets [PLTs] , plasma, and cryoprecipitate). However, other than recommendations for prophylactic PLT transfusions in hospitalized patients with AL and PLT levels of less than 10 3 10 9 /L, [1] [2] [3] variables for blood product transfusions are institution and provider dependent. Given lack of consensus, evidence-based transfusion guidelines for AL patients, we hypothesized that there would be wide variations in blood product transfusion practices for AL patients at both the individual provider and the institutional levels among providers who manage patients with AL in the United States. To test this hypothesis, we designed a Web-based survey to evaluate transfusion practice patterns for AL patients in a variety of care settings.
MATERIALS AND METHODS
For this cross-sectional study, we developed a 31-question survey (Appendix S1, available as supporting information in the online version of this paper) to query health care providers caring for patients with AL. We asked about the existence of institutional guidelines for transfusion of blood products and product-specific transfusion thresholds for RBCs, PLTs, and cryoprecipitate in various settings including inpatient and outpatient and before procedures. We also queried the use of irradiated, washed, cytomegalovirus (CMV) seronegative, and leukoreduced RBCs and irradiated, washed, volume-reduced, and CMV-seronegative PLTs. The survey was approved by the respective cooperative group chairs and was administered through the Webbased SurveyMonkey platform. A link to the survey was distributed via e-mail to all members of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group, Alliance for Clinical Trials in Oncology (Alliance), Cancer Trial Support Unit (CTSU), and Southwest Oncology Group (SWOG) by the ECOG-ACRIN Clinical Education and Awareness Team. Survey distribution occurred on July 6, 2015, and closed on August 14, 2015, after five weekly reminders. Responses were anonymous, and no incentives were provided to survey respondents. We excluded incomplete surveys from the analysis.
We sought to estimate the number of providers who change RBC and PLT transfusion thresholds depending on the clinical setting (discordance) and whether it was different from that of providers who keep transfusion thresholds the same across the settings (concordance). To this end we used the McNemar statistical test to compare concordance and discordance between RBC transfusion thresholds of 7 and 8 g/dL and between PLT transfusion 
RESULTS

Study cohort
Surveys were distributed to a total of 9859 recipients including 3653 physicians, with at least 741 in direct care of patients with AL. In total, 304 unique responses were received. Of these, we excluded 138 responses as they were returned by recipients not directly treating patients with AL, and an additional 36 responses were excluded due to incomplete surveys. The final data set consisted of 130 responses, 99 of which came from physicians (76%) with the remainder provided by advance practice providers, oncology nursing staff, and pharmacists directly involved in care of patients with AL. There were 51 women (39%). The median age of all responders was 45 years (range, 26-76 years). The respondents represented 99 institutions in 37 states (Table 1) .
Transfusion thresholds
Approximately 85% (111) and 78% (102) of responders reported existing institutional transfusion guidelines for hospitalized and ambulatory AL patients, respectively. A hemoglobin (Hb) threshold of 7 g/dL or lower for RBC transfusions in asymptomatic stable hospitalized patients was reported by 61 respondents (47%), followed by 46 (35%) providers who used a Hb level of 8 g/dL. Conversely, in the outpatient setting, of 121 responses the most commonly chosen was the Hb threshold of 8 g/dL reported by 57 recipients (47%), followed by 7 g/dL in 37 (31%) and 7.5 g/dL in 16 (13%) responses (Table 2) .
With respect to PLT transfusions, a PLT level of 10 3 10 9 /L or lower was the most commonly reported threshold for stable nonbleeding hospitalized patients (81% of responders). Other choices of 15 3 10 9 /L, 20 3 10 9 /L, "only if bleeding or symptomatic," and "no specific threshold" made up the remaining 19% of responses. The PLT threshold of 10 3 10 9 /L or lower was used by 53% of providers to guide PLT transfusions in nonbleeding ambulatory patients, with an additional 30% of respondents using a higher threshold of 20 3 10 9 /L (Table  3) . For procedures, 70% of responders considered a PLT count of 10 3 10 9 /L and higher adequate for performing bone marrow (BM) biopsies and a PLT level of 50 3 10 9 /L adequate for performing lumbar punctures (LPs; Table 4 ).
Of 121 responders who specified fibrinogen thresholds, nearly half reported the threshold fibrinogen level of 100 mg/dL as a trigger for administering cryoprecipitate in the following scenarios: 46% (56) for disseminated intravascular coagulation (DIC), 49% (59) in the postasparaginase treatment setting, and 51% (62) for patients with AL other than acute promyelocytic leukemia (APL) without DIC (Table 5 ). For patients with APL, 41% (50) of respondents used the threshold of 100 mg/dL followed by 35% (42) of providers who reported using the threshold fibrinogen level of 150 mg/dL. This threshold was used by 15% of providers (18) in DIC, 11% (13) after asparaginase treatment, and 6% (7) in patients with AL other than APL without DIC. Approximately one-fifth of responders reported having no specific fibrinogen threshold for cryoprecipitate transfusion in each case: 18% (22) in DIC, 20% (24) after asparaginase treatment, and 22% (27) in patients with AL other than APL. In the setting of hypofibrinogenemia in patients with APL, 12% of providers (15) had no specific transfusion threshold.
Modifications to PLT and RBC products before transfusion
Most providers reported always using leukoreduced and irradiated RBCs (93 and 75%, respectively) in the AL population. Providers reported varying patterns of using CMV-seronegative, washed blood and PLTs. Most frequently these modifications were used in "specific circumstances," reported by 46 and 54% respondents for CMV-seronegative and washed blood, respectively (Table  6 ). Washed and CMV-seronegative PLTs were transfused in specific circumstances by 48 and 45% of providers, respectively. The remaining responses were split in similar proportions between providers who reported using CMVseronegative and washed blood and PLTs always or sometimes and those who never used blood products with these modifications (Table 7) . Single-donor apheresis PLTs were preferred by 78% respondents, and 56% used such PLTs exclusively.
Concordance and discordance of ambulatory versus inpatient transfusion patterns
Most providers used the same treatment threshold in the inpatient and outpatient settings. For RBC transfusions, responders who used the same transfusion threshold in both inpatient and ambulatory settings were considered "concordant": 32 responders (25%) used Hb levels of 7 g/dL or lower, while 38 responders (29%) maintained 8 g/dL in both settings. Among "discordant" providers, five responders (4%) used a higher Hb threshold in inpatient than in outpatient settings, and 27 providers (21%) used a lower threshold for hospitalized patients.
The difference between the number of concordant and discordant providers was determined to be significant (p < 0.001). This indicates a clear preference for the lower Hb threshold in inpatient settings among those providers who take clinical settings into account. Similarly, when responders described their use of PLT thresholds, 56 of them (43%) used the threshold of 10 3 10 9 /L in both hospitalized and ambulatory patients, while seven providers (5%) transfused at the PLT level of 20 3 10 9 /L in both clinical settings. Thirtynine responders (30%) reported using the threshold of 20 3 10 9 /L in outpatient settings while using a lower one (10 3 10 9 /L or 15 3 10 9 /L) in hospitalized patients.
Notably, two providers indicated using a higher PLT threshold in hospitalized patients. Overall, the preference among providers who take clinical settings into account was for the lower PLT thresholds in hospitalized patients (p < 0.001).
DISCUSSION
Transfusion of blood products is a key component of the supportive management in patients with AL, especially 12 showed the same or better outcomes (mortality, myocardial infarction, pulmonary edema, congestive heart failure, stroke, infection, and thromboembolism) achieved with restrictive transfusion goals. 13 However, only two studies evaluated the Hb transfusion goals for patients with AL. A small retrospective study, 14 in which 84 patients with acute myeloid leukemia received RBCs under either the restrictive or the liberal transfusion strategy (mean trigger Hb level of 8 and 9 g/dL, respectively), revealed no differences in mortality, therapy response, cardiac complications, the rates of bleeding, and the need for PLT transfusions. Similarly, a recent small prospective pilot study, 15 in which 90 patients with AL were randomized to the restrictive (7 g/dL) and liberal (8 g/dL) transfusion arms, revealed no significant difference in bleeding events, PLT transfusions, and incidence of neutropenic fever. The patients in the restrictive arm received fewer RBC units compared to those in the liberal arm (median of 8 units vs. 10 units).
In our survey of practice, 47% of responders reported using the Hb threshold of 7 g/dL for RBC transfusions in hemodynamically stable, asymptomatic nonbleeding hospitalized patients, while the threshold of 8 g/dL was reported by 35% clinicians. Such a split may suggest that the latter group followed the evidence for the RBC transfusion trigger identified in a small retrospective study mentioned above.
14 Those who chose the more restrictive threshold might have extrapolated the evidence summarized in the AABB RBC transfusion guidelines from nononcologic settings onto the population of patients with AL. However, in the setting of therapeutic myelosuppression and leukemia, it is unclear whether the restrictive transfusion trigger of 7 g/dL alters clinical outcomes since no large randomized trial has been conducted in this specific population. For ambulatory patients, a greater proportion of clinicians (47%) reported the trigger Hb level of 8 g/dL while 31% of respondents reported the threshold of
